相关报告：智研咨询发布的《2025-2031年中国工业云行业市场深度评估及投资机会预测报告》 上市公司：江西铜业（600362），安源煤业（600397），九丰能源（605090），中国稀土（000831）， 仁和药业（000650），富祥药业（300497），同和药业（300636），江中药业（600750），煌上煌 （002695），甘源食品（002991），阳光乳业（001318），百胜智能（301083），南矿集团 （001360），江铃汽车（000550） 2016-2025年1-4月江西省工业企业数统计图 数据来源：国家统计局，智研咨询整理 2025年1-4月，江西省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为19226 个，和上年同期相比，增加了547个，同比增长2.93%，占全国的比重为3.7%。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年9月8日 2、公司在任监事3人，出席3人； (二)股东大会召开的地点：江西省南昌市高新开发区火炬大街788号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长刘为权先生主持，采取现场投票与网络投票相结合的表决方式。表决方式符合《公司法》 及《公司章程》的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 3、董事会秘书出席了会议；公司其他高管列席会议。 二、议案审议情况 (二)涉及重大事项，5%以下股东的表决情况 ■ (一)非累积投票议案 1、议案名称：公司2025年半年度利润分配方案 审议结果：通过 表决情况： ■ 2、议案名称：关于续聘2025年度审计机构的议案 审议结果：通过 表决情况： ■ (三)关于议案表决的 ...

致：江中药业股份有限公司 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于江中药业股份有限公司 2025 年第一次临时股东大会的法律意见书 江中药业股份有限公司（以下简称"公司"）2025 年第一次临时股东大会（以 下简称"本次股东大会"）现场会议定于 2025 年 9 月 8 日下午 14:50 在江西省南 昌市高新开发区火炬大街 788 号公司会议室召开，国浩律师（上海）事务所（以 下简称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华人民共 和国证券法》、《中华人民共和国公司法》和《江中药业股份有限公司章程》（以 下简称《公司章程》）出具本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和股东大会表决程序、表决结果等发表法律意见。法律意 见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、法规的规定而出具。 本所律师同意将本法律意见书作为公司本次 ...

证券代码：600750 证券简称：江中药业 公告编号：2025-047 江中药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 8 日 (二)股东大会召开的地点：江西省南昌市高新开发区火炬大街 788 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 908 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 301,753,931 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 47.5206 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长刘为权先生主持，采取现场投票与网络投票相结合的表决方式。 表决方式符合《公司法》及《公司章程》的有关规定。 (五)公司董事、 ...

Group 1 - The event "China International Import Expo Goes to China Resources" was held in Huizhou, Guangdong, focusing on the health sector and attracting over 30 Fortune 500 companies [1] - The event aims to enhance cooperation between central enterprises and international partners, leveraging the opportunities in the Chinese health market [1] - China Resources Group's seven business units, including China Resources Pharmaceutical and China Resources Sanjiu, expressed import procurement needs during the event [1] Group 2 - European health companies reported that the China International Import Expo has significantly aided their market entry by connecting them with distributors, agents, and quality customers [2] - These companies are optimistic about the growth prospects in the Chinese market, citing its large scale advantage [2] - Some companies suggested that China should align its medical device market access standards more closely with international standards to facilitate broader consumer access [2]

Core Viewpoint - The Chinese herbal medicine sector is expected to see a gradual recovery in gross margins in H2 2025 as the pressure from high-priced raw materials diminishes, despite ongoing operational challenges for companies and weak OTC demand [1][2]. Group 1: Industry Performance - In H1 2025, the total revenue of 64 Chinese herbal medicine companies was 172.9 billion yuan, a year-on-year decrease of 4.95%, while the net profit excluding extraordinary items was 19.1 billion yuan, down 9.31% year-on-year [2]. - The gross margin for the sector in H1 2025 was 42.05%, a decline of 1.01 percentage points year-on-year, and the net profit margin excluding extraordinary items was 11.04%, down 0.56 percentage points year-on-year [2]. - The prices of Chinese medicinal materials have stabilized since mid-2024, with a notable decline starting in May 2025, which is expected to alleviate cost pressures in H2 2025 [2]. Group 2: Financial Metrics - The median expense ratio for the herbal medicine sector in H1 2025 was 44.5%, an increase of 1.5 percentage points compared to the same period in 2024, while the median sales expense ratio was 31.6%, a slight decrease of 0.1 percentage points [3]. - The ratio of accounts receivable plus notes receivable to total revenue was 48.8%, and the inventory to total assets ratio was 12.3%, indicating an increase in accounts receivable as a proportion of total revenue compared to 2024 [3]. - Operating cash flow showed a slight improvement year-on-year in H1 2025, indicating enhanced collection efforts by herbal medicine companies [3]. Group 3: OTC Market Dynamics - The OTC demand remains weak, with a median revenue growth rate of -7.6% and a net profit growth rate of -19.7% for 22 OTC-focused herbal medicine companies in Q2 2025, indicating greater operational pressure compared to the overall sector [4]. - The retail scale of physical pharmacies in China for H1 2025 was 296.1 billion yuan, reflecting a year-on-year decline of 2.2%, which corroborates the weak OTC demand [4]. - Despite short-term demand pressures, the consolidation of retail pharmacies is expected to accelerate the concentration of the OTC market, with leading products gaining market share [4].

Investment Rating - The report maintains an "Overweight" rating for the traditional Chinese medicine sector [4]. Core Viewpoints - The traditional Chinese medicine sector is experiencing short-term performance pressure, but there are expectations for demand recovery in the future [7][10]. - The overall revenue and profit decline in the sector has narrowed compared to 2024, indicating a gradual recovery in industry sentiment [10]. - The report highlights the importance of brand OTC products, which are expected to see market share increases despite current demand pressures [7][26]. Summary by Sections 2025H1 Performance - In 2025H1, the total revenue of traditional Chinese medicine companies reached 172.9 billion yuan, a year-on-year decrease of 4.95% [10]. - The net profit excluding non-recurring items was 19.1 billion yuan, down 9.31% year-on-year [10]. - The operating cash flow improved significantly, reaching 16.96 billion yuan, an increase of 30.77% year-on-year [10]. OTC Market Analysis - The OTC segment is under pressure, with a median revenue growth rate of -7.6% and a net profit decline of -19.7% in Q2 2025 [26]. - The retail market for pharmaceuticals and non-pharmaceuticals in China saw a slight decline, with a total of 296.1 billion yuan in H1 2025, down 2.2% year-on-year [26][29]. - The report notes that the concentration of leading OTC brands is increasing, with significant market share gains for products like Huaren Sanjiu's Ganmaoling Granules [26][31]. Cost and Margin Outlook - The median gross margin for the sector in 2025H1 was 42.05%, a decrease of 1.01 percentage points year-on-year [10]. - The report anticipates a recovery in gross margins in H2 2025 as the pressure from high-priced raw materials eases [13]. - The median expense ratio for the sector was 44.5%, reflecting a stable cost structure despite slight increases in certain areas [15]. R&D and Innovation - The median R&D expense ratio for the sector remains around 3%, with leading companies like Kangyuan Pharmaceutical and Tian Shili investing over 10% of their revenue in R&D [24]. - The report emphasizes the potential for revaluation of innovative pipelines as companies increase their R&D investments [7].

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 to discuss key proposals including the profit distribution plan for the first half of 2025 and the reappointment of the auditing firm for the year [1][4]. Meeting Procedures - The meeting will be conducted in accordance with relevant laws and regulations to ensure the rights of shareholders and maintain order [1][2]. - Only authorized shareholders and specific invited personnel are allowed to attend the meeting, and registration is required prior to the meeting [1][2]. - Shareholders have the right to speak, inquire, and vote, but must register to speak in advance and adhere to time limits [2][3]. Meeting Agenda - The meeting is scheduled for September 8, 2025, at 14:50 in Nanchang, Jiangxi Province [1][4]. - The agenda includes the profit distribution plan for the first half of 2025 and a proposal to reappoint KPMG Huazhen as the auditing firm for 2025 [1][4]. Profit Distribution Plan - The company proposes a cash dividend of 5 yuan (including tax) for every 10 shares, which amounts to a total distribution of approximately 317.5 million yuan based on the total share capital of 634,996,022 shares as of June 2025 [4][5]. - This cash dividend represents 60.78% of the net profit attributable to the parent company for the first half of 2025 [4][5]. Auditing Firm Reappointment - The company intends to reappoint KPMG Huazhen as its auditing firm for 2025, ensuring continuity and stability in audit services [6][8]. - KPMG Huazhen has a strong track record, with over 41 billion yuan in total revenue for 2024, of which over 40 billion yuan was from audit services [6][7]. - The firm has audited 127 listed companies in 2024, with a total audit fee of approximately 682 million yuan [7][8].

2025 年第一次临时股东大会会议材料 南 昌 二〇二五年九月 江中药业股份有限公司 2025 年第一次临时股东大会会议材料 江中药业股份有限公司 江中药业股份有限公司 2025 年第一次临时股东大会会议材料 议案目录 | 议案一：公司 | 2025 | 年半年度利润分配方案 | 6 | | --- | --- | --- | --- | | 议案二：关于续聘 | | 2025 年度审计机构的议案 | 7 | 二、会议期间全体出席会议人员应以维护股东合法权益、确保大会正 常秩序、提高议事效率为原则，认真履行法定职责。 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股 东（或其授权代表）、董事、监事、董事会秘书、高级管理人员、聘请的 律师和董事会邀请参会的人员外，公司有权依法拒绝其他人士入场。 四、出席会议的股东（或其授权代表）必须在会议召开前十分钟向大 会秘书处办理签到、登记手续。 五、出席会议的股东（或其授权代表）依法享有发言权、质询权和表 决权等各项股东权益。股东（或其授权代表）要求发言的，应当在股东大 会召开前十分钟至大会秘书处进行发言登记，大会秘书处将按股东发言登 记时间先后顺序，安排股东 ...

Group 1 - The core viewpoint of the article highlights the significant changes in stock holdings by securities firms during the second quarter, with a focus on industries such as basic chemicals, machinery, automotive, and pharmaceuticals [1] - Securities firms collectively increased their positions in 63 stocks during the second quarter, with notable additions including Zhongke Titanium White, New Mileage, Jiangzhong Pharmaceutical, and Yuntianhua [1] - Several companies, including Chuanheng Co., Furan Energy, Ruida Futures, and Zhejiang Huaye, received attention from at least three securities firms, indicating strong interest [1] Group 2 - In terms of holding scale, data from Choice shows that Jiangsu Bank, Yong'an Futures, CITIC Securities, and Sinopec have the highest total shareholdings among securities firms [1] - As of the closing price on June 30, 2025, Jiangsu Bank leads with a holding market value of 11.026 billion yuan, followed by CITIC Securities and Yong'an Futures with 9.208 billion yuan and 6.507 billion yuan respectively [1] - Other companies such as Muyuan Foods, Cangge Mining, Sinopec, and Guangqi Technology also have significant market values in securities holdings [1]